Friday, 18 October 2013

Stem Cell Therapeutics strengthens CD47 franchise with acquistion of Complementary Antibody Program

Stem Cell Therapeutics, a biopharmaceutical immuno-oncology company developing cancer stem cell-related therapeutics, issued a press today announcing that it has entered into an optional agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a).

The technology was developed by scientists at the University Health Network, the University of Toronto, through the Toronto Recombinant Antibody Centre (TRAC), and The Hospital for Sick Children (SickKids), in Toronto, Ontario.


SIRPa is the ligand of CD47, a molecule upregulated on many hematological and solid tumors. CD47 delivers a "do not eat" signal that su ppresses macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to escape immune-mediated destruction. Stem Cell Therapeutics (SCT) is currently developing a CD47 antagonist, using a modified version of the native SIRPa protein fused to an immunoglobulin Fc region. This SIRPaFc fusion protein has shown remarkable anti-leukemic activity both in vitro and in human xenograft models, and SCT recently announced that the program has entered the IND-enabling phase of drug development. The company expects to report further updates at the upcoming annual meeting of the American Society of Hematology (December 7-10, 2013).

"Targeting the CD47/SIRPa pathway can eliminate bot h bulk cancer cells and cancer stem cells, and engages both the innate and the adaptive arms of the immune system. Antibody blockade of SIRPa is a promising approach to activate the anti-tumor activity of macrophages against both liquid and solid tumors, and has the potential as both a monotherapy and combination therapy with other anti-cancer antibodies." commented SCT's Chief Scientific Officer, Dr. Bob Uger.

"The CD47/SIRPa axis is one of the most promising a nd compelling next-generation immunotherapy targets in the fight against cancer. Having recently an nounced the advancement of our SIRPaFc program into formal IND-enabling studies, a program we believe is the best-in-class CD47 antagonist currently in development, reinforcing our industry-leading position in this pathway with a complementary antibody program against the SIRPa protein makes eminent sense." remarked SCT's Chief Executive Officer, Dr. Niclas Stiernholm. 

The execution of the definitive license agreement is subject to final due-diligence and certain conditions being met by SCT over the next nine months. The license agreement will contain customary terms and provisions for assets at this stage of development, including an initial license consideration, milestone payments, royalties on sales and sublicensing terms.

Reference

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !